Castle Biosciences Inc
NASDAQ:CSTL
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
Castle Biosciences Inc
NASDAQ:CSTL
|
1B USD |
Loading...
|
|
| US |
|
CVS Health Corp
NYSE:CVS
|
97.7B USD |
Loading...
|
|
| US |
C
|
Cigna Group
XMUN:CGN
|
61.7B EUR |
Loading...
|
|
| US |
|
Cigna Corp
NYSE:CI
|
73.4B USD |
Loading...
|
|
| DE |
|
Fresenius SE & Co KGaA
XETRA:FRE
|
27.3B EUR |
Loading...
|
|
| DE |
|
Fresenius Medical Care AG
XMUN:FME
|
23.6B EUR |
Loading...
|
|
| US |
|
Laboratory Corporation of America Holdings
NYSE:LH
|
22.9B USD |
Loading...
|
|
| US |
|
Quest Diagnostics Inc
NYSE:DGX
|
21.1B USD |
Loading...
|
|
| DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
11.7B EUR |
Loading...
|
|
| US |
|
Guardant Health Inc
NASDAQ:GH
|
13.3B USD |
Loading...
|
|
| US |
|
DaVita Inc
NYSE:DVA
|
10.1B USD |
Loading...
|
Market Distribution
| Min | -4 418 600% |
| 30th Percentile | -9.6% |
| Median | 3.1% |
| 70th Percentile | 11.3% |
| Max | 1 135 400% |
Other Profitability Ratios
Castle Biosciences Inc
Glance View
Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The company is headquartered in Friendswood, Texas and currently employs 342 full-time employees. The company went IPO on 2019-07-25. The company is focused on providing physicians and their patients with personalized, clinically actionable information to clinicians and their patients to inform treatment decisions and improve health outcomes. The firm markets five multi-analyte assays with algorithmic analysis (MAAA) tests for use in the dermatologic, ocular and gastroenterology fields: DecisionDx-Melanoma, DecisionDx-SCC, Comprehensive Diagnostic Offering (CDO), DecisionDx-UM and TissueCypher Barrett’s Esophagus Assay. DecisionDx-Melanoma is risk stratification gene expression profile (GEP) test developed to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. DecisionDx-SCC, a 40-gene expression profile test that uses an individual patient’s tumor biology to predict individual risk of squamous cell carcinoma (SCC) metastasis for patients with one or more risk factors.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Castle Biosciences Inc is -3.6%, which is above its 3-year median of -16.3%.
Over the last 3 years, Castle Biosciences Inc’s Net Margin has increased from -42.8% to -3.6%. During this period, it reached a low of -53% on Jun 30, 2023 and a high of 5.5% on Dec 31, 2024.
